KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression

Cancer Biology and Therapy

Volumn 9, Issue 7, 2010, Pages 507-513

  Zhou, Yanbin ^a,b   Hofstetter, Wayne L ^b   He, Yong ^b   Hu, Wenxian ^b   Pataer, Abujiang ^b   Wang, Li ^b   Wang, Ji ^b   Zhou, Yihong ^c   Yu, Liping ^d   Fang, Bingliang ^b   Swisher, Stephen G ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Ziren Research LLC   (United States)

Author keywords

Carcinoma; KLF4; Lung; SPARC; Tumor invasion

Indexed keywords

KRUPPEL LIKE FACTOR 4; OSTEONECTIN; PROTEIN P21;

ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION;

EID: 77953693342     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.7.11106     Document Type: Article

References (51)

1. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981; 26:99-105.
2. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Human Pathol 1999; 30:339-44. (Pubitemid 29125155)
3. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003; 278:15951-7. (Pubitemid 36799713)
4. Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 2002; 62:6270-7. (Pubitemid 35244481)
5. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146:95-100.
6. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004; 64:3037-45. (Pubitemid 38581402)
7. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000; 6:1140-9. (Pubitemid 30159378)
8. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, et al. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 1999; 189:46-52. (Pubitemid 29406818)
9. Prenzel KL, Warnecke-Eberz U, Xi H, Brabender J, Baldus SE, Bollschweiler E, et al. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncol Reports 2006; 15:1397-401. (Pubitemid 43329262)
10. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001; 166:2495-9. (Pubitemid 33065342)
11. Kato Y, Nagashima Y, Baba Y, Kawano T, Furukawa M, Kubota A, et al. Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int J Mol Med 2005; 16:263-8.
12. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005; 113:789-97. (Pubitemid 40101261)
13. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003; 63:5376-80. (Pubitemid 37139854)
14. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 2006; 66:7516-23. (Pubitemid 44289206)
15. Smit DJ, Gardiner BB, Sturm RA. Osteonectin down-regulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 2007; 121:2653-60.
16. Sosa MS, Girotti MR, Salvatierra E, Prada F, de Olmo JA, Gallango SJ, et al. Proteomic analysis identified N-cadherin, clusterin and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics 2007; 7:4123-34. (Pubitemid 350190284)
17. Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 2007; 26:4084-94. (Pubitemid 46920166)
18. Weaver MS, Workman G, Sage EH. The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 2008; 283:22826-37.
19. Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994; 125:929-43.
20. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Med 1997; 3:171-6. (Pubitemid 27064701)
21. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 2007; 121:567-75.
22. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995; 64:70-5.
23. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001; 159:609-22.
24. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, et al. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005; 65:7370-7.
25. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, et al. Drastic downregulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 2005; 65:2746-54.
26. Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res 2008; 68:4631-9.
27. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188:143-60.
28. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76.
29. Hu W, Hofstetter W, Li H, Zhou Y, He Y, Pataer A, et al. Putative Tumor-Suppressor Function of Krüppel-Like Factor 4 in Primary Lung Carcinoma. Clin Cancer Res 2009; 15:5688-95.
30. Rowland BD, Peeper DS, Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nature Rev Cancer 2006; 6:11-23.
31. WAF1/Cip1 promoter. J Biol Chem 2000; 275:18391-8.
32. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008; 214:283-93.
33. Behmoaram E, Bijian K, Bismar TA, Alaoui-Jamali MA. Early stage cancer cell invasion: signaling, biomarkers and therapeutic targeting. Front Biosci 2008; 13:6314-25.
34. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999; 59:4453-7.
35. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008; 27:691-705.
36. Siddiq F, Sarkar FH, Wali A, Pass HI, Lonardo F. Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. Lung Cancer 2004; 45:197-205.
37. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza- 2′deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer 2008; 98:1810-9.
38. Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, et al. Aberrant methylation of SPARC in human lung cancers. Br J Cancer 2005; 92:942-8.
39. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002; 21:7077-91.
40. Mettouchi A, Cabon F, Montreau N, Vernier P, Mercier G, Blangy D, et al. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 1994; 13:5668-78.
41. Philipsen S, Suske G. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 1999; 27:2991-3000.
42. Shie JL, Chen ZY, Fu M, Pestell RG, Tseng CC. Gut-enriched Kruppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res 2000; 28:2969-76.
43. Chen ZY, Shie JL, Tseng CC. Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells. J Biol Chem 2002; 277:46831-9.
44. Young MF, Findlay DM, Dominguez P, Burbelo PD, McQuillan C, Kopp JB, et al. Osteonectin promoter. DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells. J Biol Chem 1989; 264:450-6.
45. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene 2004; 23:395-402.
46. Yang Y, Goldstein BG, Chao HH, Katz JP. KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther 2005; 4:1216-21.
47. Ton-That H, Kaestner KH, Shields JM, Mahatanankoon CS, Yang VW. Expression of the gut-enriched Kruppel-like factor gene during development and intestinal tumorigenesis. FEBS Lett 1997; 419:239-43.
48. Schulz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 2006; 10:100-25.
49. Ohnishi S, Ohnami S, Laub F, Aoki K, Suzuki K, Kanai Y, et al. Downregulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun 2003; 308:251-6.
50. Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 2008; 68:7403-8.
51. Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro-Oncol 2005; 7:485-94.